RxDoctor Payments Data

Cherico Bowman

Family · Memphis, TNNPI 1740956416

Payments from drug & device makers

$2,398in general payments, 2019–2025

Across 77 payments — averaging $31.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$610
  • Lilly USA, LLC$400
  • Novo Nordisk$298
  • Dexcom, Inc.$229
  • GSK$214
  • C2n Diagnostics, LLC$170
  • plus $476 from 8 others

What the payments were for

  • Food & beverage$2,398100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,398 in reported general payments places this provider in the 80th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$5,655
Medicare patients
26
Services billed
96

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol51$61,159
OzempicSemaglutide35$37,034
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$26,277
JardianceEmpagliflozin19$24,708
KerendiaFinerenone11$18,103
Albuterol Sulfate HfaAlbuterol Sulfate61$1,977
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$1,906
Atorvastatin Calcium160$1,386
Amlodipine Besylate212$1,338
Potassium Chloride74$1,289
Omeprazole70$1,212
Diclofenac Sodium36$792
Levetiracetam16$631
Duloxetine Hcl22$601
Pantoprazole Sodium50$558

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$298$37,03435 claims
GSKTrelegy Ellipta$214$26,27717 claims
BayerKerendia$610$18,10311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 6,706 family providers in Tennessee.

Other family in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →